Drugs / Alvircept sudotox
Alvircept sudotox
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000743 | ? → May 1995 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00002087 | — | HIV infectious disease | Pharmacia and Upjohn | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alvircept sudotox | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002087 ↗ |
| Known as | sCD4-PE40 | “To investigate the safety and tolerance of an increasing number of infusions per week of alvircept sudotox ( sCD4-PE40; soluble CD4-Pseudomonas exotoxin ) at a fixed dose when...” NCT00002087 ↗1“To determine the safety and tolerance of alvircept sudotox (sCD4-PE40) given at various dosing intervals and concentrations.” NCT00000743 ↗ |
| Known as | U-85,855 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108842 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108842 ↗ |
| Route | Intravenous | “single IV weekly dose” NCT00000743 ↗ |